PMID: 6168929Jun 1, 1981Paper

Successful immunization against experimental allergic encephalomyelitis with myelin basic protein-sensitized allogeneic lymphocytes

Neurochemical Research
G A Hashim

Abstract

Prevention and suppression of experimental allergic encephalomyelitis were demonstrated in rats, guinea pigs, and rabbits immunized with allogeneic, but not with syngeneic lymphocytes from susceptible donors sensitized to myelin basic protein (MBP). Donor lymphnode, splenic, or peripheral blood lymphocytes were effective in inducing a state of unresponsiveness to an encephalitogenic challenge in either of the three species. Unresponsiveness was not obtained in recipients immunized with sensitized allogenic lymphocytes and simultaneously challenged with MBP suggesting that a time lapse between immunization and challenge is necessary for the development of protective immunity. Induced in immunized recipients, unresponsiveness was transferred into normal syngeneic recipients with immunoglobulin-G (IgG) isolated from protected donors before challenge. Furthermore, both immunized and IgG recipients failed to develop cell-mediated immunity after challenge with MBP. The results show that prevention and suppression of EAE was mediated by antibodies which inhibited the development of delayed type hypersensitivity to the challenging antigen.

References

Jul 1, 1975·Proceedings of the Society for Experimental Biology and Medicine·G A HashimL E Stevens
Jan 21, 1972·Science·B Benacerraf, H O McDevitt
Jun 1, 1969·Archives of Biochemistry and Biophysics·E H EylarL V Brown
May 1, 1963·The Journal of Experimental Medicine·P Y PATERSON, S M HARWIN
Jan 1, 1963·International Archives of Allergy and Applied Immunology·M FLAX, B H WAKSMAN
Jan 1, 1960·The Journal of Experimental Medicine·P Y PATERSON

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.